靶向治疗联合放化疗同步治疗在肺癌脑转移患者中的临床效果研究(1)
【摘要】 目的：研究靶向治疗联合放化疗同步治疗在肺癌脑转移患者中的效果。方法：选取2016年2月-2018年7月笔者所在医院收治的84例肺癌脑转移患者，按就诊先后分成观察组(n=42)与对照组(n=42)，对照组采用放化疗同步治疗，观察组采用靶向治疗联合放化疗同步治疗，观察两组治疗效果及不良反应情况、1年生存率、局部复发率、远处转移率。结果：观察组治疗总有效率(97.62%)高于对照组(83.33%)，不良反应发生率(9.52%)低于对照组(26.19%)，差异均有统计学意义(P<0.05);观察组1年生存率(54.76%)高于对照组(19.05%)，局部复发率(9.52%)低于对照组(35.71%)，远处转移率(7.14%)低于对照组(28.57%)，差异均有统计学意义(P<0.05)。结论：靶向治疗联合放化疗同步治疗在肺癌脑转移患者的应用，有效提升治疗效果，可减少不良反应，提高治疗安全性，临床应用价值高。
【关键词】 肺癌脑转移 靶向治疗 放化疗同步治疗 疗效 安全性
[Abstract] Objective： To study the effect of targeted therapy combined with radiotherapy and chemotherapy in patients with brain metastasis in lung cancer. Method： From February 2016 to July 2018， 84 patients with brain metastasis from lung cancer were selected， and were divided into the observation group (n=42) and the control group (n=42). The control group was treated with radiotherapy and chemotherapy simultaneously， and the observation group was treated with targeted therapy combined with radiotherapy and chemotherapy simultaneously. The therapeutic effect and adverse reactions， 1-year survival rate， local recurrence rate and distant metastasis rate of the two groups were observed. Result： The total effective rate (97.62%) in the observation group was higher than that in the control group (83.33%)， the incidence of adverse reactions (9.52%) in the observation group was lower than that in the control group (26.19%)， the differences were statistically significant (P<0.05). The 1-year survival rate (54.76%) in the observation group was higher than that in the control group (19.05%)， the local recurrence rate (9.52%) in the observation group was lower than that in the control group (35.71%)， and the distant recurrence rate (7.14%) in the observation group was lower than that of the control group (28.57%)， the differences were statistically significant (P<0.05). Conclusion： Targeted therapy combined with concurrent radiotherapy and chemotherapy in the treatment of brain metastasis of lung cancer can effectively improve the treatment effect， reduce adverse reactions， improve the safety of treatment， and has high clinical application value.
腦转移往往导致肺癌治疗失败，有可能造成肺癌患者死亡。若患者有脑转移，采用化疗、靶向药物难以达到良好效果[1]。临床对于患者进行治疗时，通常实施全脑放疗，但照射剂量会导致临床效果受到影响，且患者生存期明显缩短，由于血脑屏障，使得化疗药物难以到达病灶，所以临床效果并不理想[2-3]。全脑放疗对于脑部肿瘤具有一定效果，但采用全脑放疗时，需要较多条件，因多种因素影响，且需严格控制食欲剂量，导致临床效果受限[4]。本文选取84例肺癌脑转移患者，探讨靶向治疗联合放化疗同步治疗的疗效及安全性，报道如下。
1 资料与方法
1.1 一般资料
选取2016年2月-2018年7月笔者所在医院收治的84例肺癌脑转移患者。患者均采用影像学技术、病理组织学进行确诊，经MR检查显示患者此脑部转移性病灶;预计生存期超过3个月。排除标准：对研究相关药物不耐受;严重肝肾功能障碍;依从性差。按就诊先后分成观察组(n=42)与对照组(n=42)。观察组中男22例，女20例;年龄43～76岁，平均(59.63±2.61)岁;大细胞癌3例，腺鳞癌5例，腺癌29例，鳞癌5例;肿瘤家族史5例。对照组中男23例，女19例;年龄43～77岁，平均(59.60±2.59)岁;大细胞癌3例，腺鳞癌5例，腺癌29例，鳞癌5例;肿瘤家族史4例。两组基础资料比较差异无统计学意义(P>0.05)。, 百拇医药(陈煜)
【关键词】 肺癌脑转移 靶向治疗 放化疗同步治疗 疗效 安全性
[Abstract] Objective： To study the effect of targeted therapy combined with radiotherapy and chemotherapy in patients with brain metastasis in lung cancer. Method： From February 2016 to July 2018， 84 patients with brain metastasis from lung cancer were selected， and were divided into the observation group (n=42) and the control group (n=42). The control group was treated with radiotherapy and chemotherapy simultaneously， and the observation group was treated with targeted therapy combined with radiotherapy and chemotherapy simultaneously. The therapeutic effect and adverse reactions， 1-year survival rate， local recurrence rate and distant metastasis rate of the two groups were observed. Result： The total effective rate (97.62%) in the observation group was higher than that in the control group (83.33%)， the incidence of adverse reactions (9.52%) in the observation group was lower than that in the control group (26.19%)， the differences were statistically significant (P<0.05). The 1-year survival rate (54.76%) in the observation group was higher than that in the control group (19.05%)， the local recurrence rate (9.52%) in the observation group was lower than that in the control group (35.71%)， and the distant recurrence rate (7.14%) in the observation group was lower than that of the control group (28.57%)， the differences were statistically significant (P<0.05). Conclusion： Targeted therapy combined with concurrent radiotherapy and chemotherapy in the treatment of brain metastasis of lung cancer can effectively improve the treatment effect， reduce adverse reactions， improve the safety of treatment， and has high clinical application value.
腦转移往往导致肺癌治疗失败，有可能造成肺癌患者死亡。若患者有脑转移，采用化疗、靶向药物难以达到良好效果[1]。临床对于患者进行治疗时，通常实施全脑放疗，但照射剂量会导致临床效果受到影响，且患者生存期明显缩短，由于血脑屏障，使得化疗药物难以到达病灶，所以临床效果并不理想[2-3]。全脑放疗对于脑部肿瘤具有一定效果，但采用全脑放疗时，需要较多条件，因多种因素影响，且需严格控制食欲剂量，导致临床效果受限[4]。本文选取84例肺癌脑转移患者，探讨靶向治疗联合放化疗同步治疗的疗效及安全性，报道如下。
1 资料与方法
1.1 一般资料
选取2016年2月-2018年7月笔者所在医院收治的84例肺癌脑转移患者。患者均采用影像学技术、病理组织学进行确诊，经MR检查显示患者此脑部转移性病灶;预计生存期超过3个月。排除标准：对研究相关药物不耐受;严重肝肾功能障碍;依从性差。按就诊先后分成观察组(n=42)与对照组(n=42)。观察组中男22例，女20例;年龄43～76岁，平均(59.63±2.61)岁;大细胞癌3例，腺鳞癌5例，腺癌29例，鳞癌5例;肿瘤家族史5例。对照组中男23例，女19例;年龄43～77岁，平均(59.60±2.59)岁;大细胞癌3例，腺鳞癌5例，腺癌29例，鳞癌5例;肿瘤家族史4例。两组基础资料比较差异无统计学意义(P>0.05)。, 百拇医药(陈煜)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌